29/07/2026 The US FDA Grants RMAT & Fast Track to Allogene’s Cema‑cel for first‑Line LBCL consolidation The US FDA Grants RMAT & Fast Track to Allogene’s Cema‑cel for first‑Line LBCL consolidation (Ref) RMAT & Fast Track status granted to cemacabtagene ansegedleucel (cema‑cel; CAR T‑cell therapy) for the treatment of adult patients with large B-cell lymphoma (LBCL) who, at the completion of first-line therapy, are in complete or partial response suitable for observation but t

Renal cell carcinoma (RCC) stands as the predominant form of kidney cancer, comprising about 90% of kidney cancer cases. It accounts for roughly 3% of all cancer diagnoses, with a notably higher occurrence in Western countries, likely linked to the increased detection of small renal masses. Despite advancements in targeted therapies and immunotherapies, the prognosis for stage IV RCC remains challenging, with a 5-year survival rate of only 17%. Furthermore, non-clear cell RCC